Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M34.4Revenue (TTM) $M0.6Net Margin (%)-5,892.6Altman Z-Score-12.6
Enterprise Value $M8.6EPS (TTM) $2.8Operating Margin %-5,162.0Piotroski F-Score3
P/E(ttm)1.1Beneish M-Score-2.0Pre-tax Margin (%)-5,914.9Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %-12.1Quick Ratio5.0Cash flow > EarningsY
Price/Sales24.85-y EBITDA Growth Rate %-34.9Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-76.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-261.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with AEZS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AEZSFirst Eagle Investment 2010-03-31 Sold Out $474 - $558.06
($499.42)
$ 3.46-99%Sold Out0
AEZSFirst Eagle Investment 2009-12-31 Reduce-0.02%$473.4 - $750
($607.39)
$ 3.46-99%Reduce -91.09%208
AEZSFirst Eagle Investment 2009-09-30 Buy 0.02%$534 - $1698
($960.59)
$ 3.46-100%New holding2,330
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AEZS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


AEZS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ernst, JrgenDirector 2014-11-12Buy600$60-94.23view
Ernst, JrgenDirector 2014-11-12Buy394$61.79-94.4view
Ernst, JrgenDirector 2014-11-12Buy76$61.49-94.37view
Ernst, JrgenDirector 2014-11-12Buy31$61.4-94.36view
Ernst, JrgenDirector 2014-11-12Buy149$61.46-94.37view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy85$56.5-93.88view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy10$56.97-93.93view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy344$57-93.93view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy30$57.5-93.98view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy1,281$58-94.03view

Quarterly/Annual Reports about AEZS:

    News about AEZS:

    Articles On GuruFocus.com
    Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
    Can Keryx Succeed Without Partnership? Apr 24 2012 
    Keryx Still Has High Potential from Zerenex Apr 12 2012 
    Opportunistic Coat-tailing Jan 05 2010 

    More From Other Websites
    09.14.2016 Aeterna Zentaris Announces Expiration of Remaining Series B Warrants Sep 14 2016
    Aeterna Zentaris Announces Expiration of Remaining Series B Warrants Sep 14 2016
    Aeterna Zentaris to Present at Upcoming Aegis Capital Corp. 2016 Growth Conference in Las Vegas,... Sep 12 2016
    Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New... Sep 06 2016
    Aeterna Zentaris reports 2Q loss Aug 09 2016
    Aeterna Zentaris reports 2Q loss Aug 09 2016
    08.09.2016 Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
    Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
    08.08.2016 Aeterna Zentaris Expands Promotion of APIFINY® into Florida Aug 08 2016
    Aeterna Zentaris Expands Promotion of APIFINY® into Florida Aug 08 2016
    08.01.2016 Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex™ in... Aug 01 2016
    Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex™ in Israel Aug 01 2016
    07.27.2016 Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on... Jul 27 2016
    Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on August 9, 2016 Jul 27 2016
    07.01.2016 Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for... Jul 01 2016
    Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
    Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
    05.23.2016 Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board Jun 16 2016
    06.06.2016 Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex™ During 2016... Jun 16 2016
    06.14.2016 Aeterna Zentaris Announces IND Submission by Sinopharm A-Think Jun 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)